Search Results
[Webinar] NS Pharma Provides Viltolarsen Update - November 2019
Webinar: NS Pharma Announcement of VILTEPSO™ (August 2020)
Webinar: Viltepso, An FDA-Approved Treatment for Patients Amenable to Exon 53 Skipping (March 2023)
[Webinar] NS Pharma's Exon 53 Skipping Program Update - April 2018
Recently Reported Updates - NS Pharma (PPMD's 2021 Virtual Annual Conference)
Webinar: Update on Investigational Suvodirsen in Duchenne Muscular Dystrophy - Dec 2019
Webinar: Viltepso - A Treatment Option for Patients Amenable to Exon 53 Skipping (April 2021)
physiological response of Viltolarsen
Treatments in Development for DMD
Our New Duchenne Basics: Why Data Makes the Difference [PPMD's 2017 Connect Conference]
Perron Institute Professor Steve Wilton talks about pioneering drugs for Duchenne muscular dystrophy
Viltolarsen | Viltepso | Group 48
![[Webinar] NS Pharma Provides Viltolarsen Update - November 2019](https://img.youtube.com/vi/6r1_agRAAx4/hqdefault.jpg)
![[Webinar] NS Pharma's Exon 53 Skipping Program Update - April 2018](https://img.youtube.com/vi/SsOx8OG0yqY/hqdefault.jpg)
![Our New Duchenne Basics: Why Data Makes the Difference [PPMD's 2017 Connect Conference]](https://img.youtube.com/vi/zMMZ99qjPFc/hqdefault.jpg)
